For: | Halász T, Horváth G, Pár G, Werling K, Kiss A, Schaff Z, Lendvai G. miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol 2015; 21(25): 7814-7823 [PMID: 26167081 DOI: 10.3748/wjg.v21.i25.7814] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i25/7814.htm |
Number | Citing Articles |
1 |
Javad Moayedi, Tayebeh Hashempour, Zahra Musavi, Ehsan Arefian, Mahmood Naderi, Mohamad Reza Heidari, Behzad Dehghani, Zahra Hasanshahi, Shahin Merat. Evaluation of miR-122 Serum Level and IFN-λ3 Genotypes in Patients with Chronic HCV and HCV-Infected Liver Transplant Candidate. MicroRNA 2021; 10(1): 58 doi: 10.2174/2211536609666201217101414
|
2 |
Juan Zhao, Yuelei Zhao, Hongyu Qin, Yun Ye, Liwei Zhang, Ruike Ding, Wenbin Cao, Yanru Zhang, Chenjing Duan, Haoze Leng, Yandong Li, Bo Wang, Liangshuo Hu, Enqi Liu, Pengxiang Qu. Characterization of small RNAs in the spleen of MASH in a non-human primate model. Genomics 2024; 116(6): 110953 doi: 10.1016/j.ygeno.2024.110953
|
3 |
Richard Taubert, Katharina Luise Hupa-Breier, Elmar Jaeckel, Michael P. Manns. Novel therapeutic targets in autoimmune hepatitis. Journal of Autoimmunity 2018; 95: 34 doi: 10.1016/j.jaut.2018.10.022
|
4 |
Abdelfattah M. Attallah, Dalia Omrang, Mohamed M. Omran, Mohamed A. Abdelrazek, Rania Zayed, Riham El Essawey, Sameh Saif, Azza Farid, Mohamed Hassany, Ayman Yosry, Ashraf Omar. Extracellular Matrix Proteins Substantiate IL-28B T allele Effect on Histological Outcome of Chronic Hepatitis C. Annals of Hepatology 2018; 17(4): 569 doi: 10.5604/01.3001.0012.0918
|
5 |
Xingtao Zhao, Xinyan Xue, Zhifu Cui, Felix Kwame Amevor, Yan Wan, Ke Fu, Cheng Wang, Cheng Peng, Yunxia Li. microRNAs‐based diagnostic and therapeutic applications in liver fibrosis. WIREs RNA 2023; 14(4) doi: 10.1002/wrna.1773
|
6 |
ZongYang Wu, JinBo Wang, JiYe Feng, LiPing Ying. MicroRNA-122-5p prevents proliferation and promotes apoptosis of hepatic stellate cells by suppressing the cellular-Abelsongene/histone deacetylases 2 pathway. Human & Experimental Toxicology 2022; 41 doi: 10.1177/09603271221084672
|
7 |
Tomoyuki Suehiro, Hisamitsu Miyaaki, Yasuko Kanda, Hidetaka Shibata, Takuya Honda, Eisuke Ozawa, Satoshi Miuma, Naota Taura, Kazuhiko Nakao. Serum exosomal microRNA‑122 and microRNA‑21 as predictive biomarkers in transarterial chemoembolization‑treated hepatocellular carcinoma patients. Oncology Letters 2018; doi: 10.3892/ol.2018.8991
|
8 |
Guohua Lou, Ying Yang, Feifei Liu, Bingjue Ye, Zhi Chen, Min Zheng, Yanning Liu. MiR‐122 modification enhances the therapeutic efficacy of adipose tissue‐derived mesenchymal stem cells against liver fibrosis. Journal of Cellular and Molecular Medicine 2017; 21(11): 2963 doi: 10.1111/jcmm.13208
|
9 |
Da-Wu Zeng, Jing Dong, Jia-Ji Jiang, Yue-Yong Zhu, Yu-Rui Liu. Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase. World Journal of Gastroenterology 2016; 22(43): 9586-9594 doi: 10.3748/wjg.v22.i43.9586
|
10 |
Shuailing Song, Xiao Li, Chong Geng, Yaoyu Guo, Yi Yang, Chunhui Wang. Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1171512
|
11 |
Chong-Yang Zhang, Wei-Gang Yuan, Pei He, Jia-Hui Lei, Chun-Xu Wang. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World Journal of Gastroenterology 2016; 22(48): 10512-10522 doi: 10.3748/wjg.v22.i48.10512
|
12 |
Agostino Di Ciaula, David Q-H Wang, Piero Portincasa. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Expert Review of Gastroenterology & Hepatology 2019; 13(2): 157 doi: 10.1080/17474124.2019.1549988
|
13 |
Qian-Qian Chen, Cheng Zhang, Ming-Qiang Qin, Jian Li, Hua Wang, De-Xiang Xu, Jian-Qing Wang. Inositol-Requiring Enzyme 1 Alpha Endoribonuclease Specific Inhibitor STF-083010 Alleviates Carbon Tetrachloride Induced Liver Injury and Liver Fibrosis in Mice. Frontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.01344
|
14 |
Manal S. Fawzy, Eman A. Toraih. MicroRNA signatures as predictive biomarkers in transarterial chemoembolization‐treated hepatocellular carcinoma. Precision Medical Sciences 2021; 10(1): 4 doi: 10.1002/prm2.12031
|
15 |
Xianxian Wu, Xingchen Du, Yuhui Yang, Xing Liu, Xue Liu, Na Zhang, Yuhan Li, Xiaoliang Jiang, Yideng Jiang, Zhiwei Yang. Inhibition of miR-122 reduced atherosclerotic lesion formation by regulating NPAS3-mediated endothelial to mesenchymal transition. Life Sciences 2021; 265: 118816 doi: 10.1016/j.lfs.2020.118816
|
16 |
Albert J. Czaja. Examining micro-ribonucleic acids as diagnostic and therapeutic prospects in autoimmune hepatitis. Expert Review of Clinical Immunology 2022; 18(6): 591 doi: 10.1080/1744666X.2022.2074839
|
17 |
Nikolay D. Yushchuk, Sergey I. Malov, Igor V Malov, Viktoriya V. Dvornichenko, Rodion I. Rasulov, Patrice N. Marche, Thomas Decaens, Zuzana Macek-Jilkova, Liliya A. Stepanenko, Oleg B. Ogarkov, Larisa S. Orlova. A study of serum miRNA-122 in hepatitis C and associated hepatocellular carcinoma. Annals of the Russian academy of medical sciences 2020; 74(6): 388 doi: 10.15690/vramn1255
|
18 |
Martha Paluschinski, Claus Kordes, Mihael Vucur, Veronika Buettner, Christoph Roderburg, Haifeng C. Xu, Prashant V. Shinte, Philipp A. Lang, Tom Luedde, Mirco Castoldi. Differential Modulation of miR-122 Transcription by TGFβ1/BMP6: Implications for Nonresolving Inflammation and Hepatocarcinogenesis. Cells 2023; 12(15): 1955 doi: 10.3390/cells12151955
|
19 |
Yanfang Guo, Hanying Wang, Rumin Lyu, Juan Wang, Ting Wang, Jingpei Shi, Lechun Lyu. Nanocarrier-Mediated Delivery of MicroRNAs for Fibrotic Diseases. Molecular Diagnosis & Therapy 2024; 28(1): 53 doi: 10.1007/s40291-023-00681-y
|
20 |
Xuguang Zhai, Fangyun Cheng, Li Ji, Xiaofei Zhu, Qing Cao, Yali Zhang, Xin Jia, Qian Zhou, Wei Guan, Yajun Zhou. Leptin reduces microRNA-122 level in hepatic stellate cells in vitro and in vivo. Molecular Immunology 2017; 92: 68 doi: 10.1016/j.molimm.2017.10.006
|
21 |
Paola Dongiovanni, Marica Meroni, Miriam Longo, Silvia Fargion, Anna Ludovica Fracanzani. miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. International Journal of Molecular Sciences 2018; 19(12): 3966 doi: 10.3390/ijms19123966
|
22 |
M. E. Khodjaeva, A. S. Khikmatullaeva, N. S. Ibadullaeva, M. A. Abdukadirova, K. E. Novak, E. V. Esaulenko. MicroRNA-122: assessment of diagnostic significance in HDV infection. Journal Infectology 2024; 16(1): 56 doi: 10.22625/2072-6732-2024-16-1-56-61
|
23 |
Alyaa S. Abdel Halim, Hassan Ahmed Rudayni, Anis Ahmad Chaudhary, Mohamed A. M. Ali. MicroRNAs: Small molecules with big impacts in liver injury. Journal of Cellular Physiology 2023; 238(1): 32 doi: 10.1002/jcp.30908
|
24 |
L. F. Torres, B. Cogliati, R. Otton. Green Tea Prevents NAFLD by Modulation of miR-34a and miR-194 Expression in a High-Fat Diet Mouse Model. Oxidative Medicine and Cellular Longevity 2019; 2019: 1 doi: 10.1155/2019/4168380
|
25 |
Xiao Lin Liu, Hai Xia Cao, Jian Gao Fan. MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease. Journal of Digestive Diseases 2016; 17(11): 708 doi: 10.1111/1751-2980.12408
|
26 |
Yonglong Yan, Xinna Deng, Xiaoran Ning, Fang Li, Jingjing Cao. Pathogenic mechanism of miR-21 in autoimmune lymphoid hyperplasia syndrome. Oncology Letters 2017; 13(6): 4734 doi: 10.3892/ol.2017.6039
|
27 |
Marco Sciveres, Silvia Nastasio, Giuseppe Maggiore. Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis. Frontiers in Pediatrics 2019; 7 doi: 10.3389/fped.2019.00382
|
28 |
Long-Yuan Zhou, Si-Nan Lin, Florian Rieder, Min-Hu Chen, Sheng-Hong Zhang, Ren Mao. Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn’s Disease: The Path From Bench to Bedside. Inflammatory Bowel Diseases 2021; 27(7): 971 doi: 10.1093/ibd/izaa321
|
29 |
Mengtao Xing, Xinzhi Wang, Robert Kirken, Ling He, Jian-Ying Zhang. Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. International Journal of Molecular Sciences 2021; 22(11): 6139 doi: 10.3390/ijms22116139
|
30 |
Shohei Kaneko, Katsunori Yanai, Hiroki Ishii, Akinori Aomatsu, Keiji Hirai, Susumu Ookawara, Kenichi Ishibashi, Yoshiyuki Morishita. miR−122−5p Regulates Renal Fibrosis In Vivo. International Journal of Molecular Sciences 2022; 23(23): 15423 doi: 10.3390/ijms232315423
|
31 |
Jian Li, Sun Qiyu, Tiezheng Wang, Boxun Jin, Ning Li. Improving the Detection of Hepatocellular Carcinoma using serum AFP expression in combination with GPC3 and micro-RNA miR-122 expression. Open Life Sciences 2019; 14(1): 53 doi: 10.1515/biol-2019-0007
|
32 |
Jieun Kim, Yang H. Yun, Youngmi Jung. Biotechnologies for Gene Therapy. 2022; : 1 doi: 10.1007/978-3-030-93333-3_1
|
33 |
Gábor Lendvai, Tímea Szekerczés, Benedek Gyöngyösi, Krisztina Schlachter, Endre Kontsek, Adrián Pesti, Attila Patonai, Klára Werling, Ilona Kovalszky, Zsuzsa Schaff, András Kiss. MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma. Pathology & Oncology Research 2019; 25(3): 1103 doi: 10.1007/s12253-018-0528-z
|
34 |
Yutong Zhou, Ni Jian, Canhua Jiang, Jie Wang. m6A modification in non-coding RNAs: Mechanisms and potential therapeutic implications in fibrosis. Biomedicine & Pharmacotherapy 2024; 179: 117331 doi: 10.1016/j.biopha.2024.117331
|
35 |
Mousumi Khatun, Ratna B. Ray. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells 2019; 8(10): 1249 doi: 10.3390/cells8101249
|
36 |
Albert J. Czaja. Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. Expert Review of Gastroenterology & Hepatology 2018; 12(6): 547 doi: 10.1080/17474124.2018.1453356
|
37 |
Wenbin Ding, Haixia Yang, Shenchu Gong, Weixiang Shi, Jing Xiao, Jinhua Gu, Yilang Wang, Bosheng He. Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis. Oncology Letters 2017; 13(5): 3409 doi: 10.3892/ol.2017.5913
|
38 |
Marta Afonso, Pedro Rodrigues, André Simão, Rui Castro. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Journal of Clinical Medicine 2016; 5(3): 30 doi: 10.3390/jcm5030030
|
39 |
Albert J. Czaja. Epigenetic Aspects and Prospects in Autoimmune Hepatitis. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.921765
|
40 |
Hendra Susanto, Chih-Hong Wang, Aulanni’am Aulanni’am, Adeodatus Yuda Handaya. Enhancing early stage of hepatocellular carcinoma: Does correlate to MicroRNA 122 and miR196a interaction?. INTERNATIONAL CONFERENCE ON BIOLOGY AND APPLIED SCIENCE (ICOBAS) 2019; 2120: 070021 doi: 10.1063/1.5115738
|
41 |
Sheng Wang, Chen Shuai, Songsen Gao, Jia Jiang, Jiajie Luan, Xiongwen Lv. Chemokine CXCL14 acts as a potential genetic target for liver fibrosis. International Immunopharmacology 2020; 89: 107067 doi: 10.1016/j.intimp.2020.107067
|
42 |
Archittapon Nokkeaw, Pannathon Thamjamrassri, Pisit Tangkijvanich, Chaiyaboot Ariyachet. Regulatory Functions and Mechanisms of Circular RNAs in Hepatic Stellate Cell Activation and Liver Fibrosis. Cells 2023; 12(3): 378 doi: 10.3390/cells12030378
|
43 |
|
44 |
Tomoko Tadokoro, Asahiro Morishita, Tsutomu Masaki. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. International Journal of Molecular Sciences 2021; 22(15): 8139 doi: 10.3390/ijms22158139
|
45 |
Dandan Zhu, Lei Lyu, Pei Shen, Jianxin Wang, Jinling Chen, Xiaolei Sun, Liuting Chen, Li Zhang, Qi Zhou, Yinong Duan. rSjP40 protein promotes PPARγ expression in LX‐2 cells through microRNA‐27b. The FASEB Journal 2018; 32(9): 4798 doi: 10.1096/fj.201700520RR
|
46 |
Mona A Hegazy, Ibrahim Abd ALgwad, Soheir Abuel Fadl, Mohamed Sayed Hassan, Laila Ahmed Rashed, Maha A Hussein. Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 2247 doi: 10.2147/DMSO.S291595
|
47 |
Ligang Ma, Jingjing Zhao, Xiaojuan Xie. Sevoflurane induces liver injury by modulating the expression of insulin‐like growth factor 1 via miR‐214. Journal of Cellular Physiology 2018; 233(9): 6742 doi: 10.1002/jcp.26382
|
48 |
Yuemin Nan, Xuemin Niu, Rongqi Wang, Suxian Zhao, Na Fu, Jinghua Du, Yang Wang, Baoyu Wang, Yuguo Zhang. microRNA‑1273g‑3p is a useful non‑invasive test for the prediction of liver fibrosis in patients with chronic hepatitis C. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.7114
|
49 |
Ting Jiang, Wenying Leng, Sen Zhong. Diagnostic Role of Circulating miRNAs in the Grading of Chronic Hepatitis B–Related Liver Fibrosis: A Systematic Review and Meta-Analysis. Laboratory Medicine 2023; 54(5): 479 doi: 10.1093/labmed/lmac151
|
50 |
Amin Derakhshanfar, Javad Moayedi , Mahjoob Vahedi , Abouzar Valizadeh. Arum conophalloides Aqueous Extract Induced Hepatotoxicity in Rat; Histopathological, Biochemical, and mir-122 Assessments. MicroRNA 2020; 9(3): 224 doi: 10.2174/2211536608666191016142400
|
51 |
Young Chang, Jae-A. Han, Suk Min Kang, Soung Won Jeong, Tom Ryu, Han Seul Park, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, So Young Jin, Seongho Ryu, Jae Young Jang, Bernard Mari. Clinical impact of serum exosomal microRNA in liver fibrosis. PLOS ONE 2021; 16(9): e0255672 doi: 10.1371/journal.pone.0255672
|
52 |
Albert J. Czaja. Missing Causality and Heritability of Autoimmune Hepatitis. Digestive Diseases and Sciences 2023; 68(4): 1585 doi: 10.1007/s10620-022-07728-w
|
53 |
Grazia Pennisi, Ciro Celsa, Antonina Giammanco, Federica Spatola, Salvatore Petta. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. International Journal of Molecular Sciences 2019; 20(22): 5613 doi: 10.3390/ijms20225613
|